NCT05093907招募中1 期
An Open-label, Single Center, Phase I/II Clinical Trial to Assess the Maximum Tolerated Dose, Safety and Efficacy of BEY1107 in Combination with Capecitabine in Patients with Metastatic Colorectal Cancer Refractory or Intolerant to Standard of Care
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 27
- 试验地点
- 1
- 主要终点
- Objective Response Rate(ORR)(Phase 2) assessed by investigator following administration of BEY1107 in combination with Capecitabine
研究概览
简要总结
This is a Phase 1/2 study to evaluate the maximum tolerated dose, safety and efficacy of BEY1107 in combination with capecitabine in patients with metastatic colorectal cancer refractory or intolerant to standard of care (SoC).
详细描述
In Phase 1, patients who experienced treatment failure of colorectal cancer with the second-line or beyond standard chemotherapy will be enrolled at each dose level of BEY1107 in combination with Capecitabine. Phase 2 will be conducted after RP2D is determined on the Phase 1 results.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 19 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Adult males and females aged over 19 years or older at the time of Informed Consent.
- •Histopathologically or cytologically diagnosed with colorectal cancer.
- •Patients with unresectable metastatic lesion(s).
- •Patients who experienced treatment failure of colorectal cancer with the second-line or beyond standard chemotherapy (including fluoropyrimidine, oxaliplatin and irinotecan).
- •Subjects who have at least one measurable or evaluable lesion as per RECIST v1.
- •Subjects with ECOG performance status 0 or
- •Women of childbearing potential who are not surgically sterile must consent to practice acceptable contraception until 6 months after the end of IP administration and also have the evidence of not being fertile.
- •Non-vasectomized men who consent to use an acceptable contraception by one-self and the partner until 3 months after the end of IP administration.
- •Patients who are fully informed of this trial, voluntarily decide to participate in the trial and provide written consent to comply with requirements for the trial.
排除标准
- •Patients who received radiation therapy, chemotherapy or biological agent including hormone therapy recently.
- •Subjects who had a surgery with general anesthesia within 4 weeks of screening.
- •Subjects with symptomatic brain metastasis.
- •Subjects with peripheral neuropathy.
- •Subjects who had findings of affecting absorptin of the IP with gastrointestinal surgery or impossible oral drug administration.
- •Subjects with systemic disease not suitable for anticancer agent administration at the discretion of the investigator.
- •Subjects who had a cardiovascular disease as of screening.
- •Subjects with history of malignancy other than basal cell carcinoma of the skin or cervical carcinoma in situ or papillary thyroid cancer appropriately treated within 5 years.
- •Gastrointestinal bleeding or ulcer.
- •Dihydro-Pyridine Dehydrogenase (DPD) deficiency.
- •Galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption.
- •Hypersensitivity to the ingredient(s) of the investigational product (BEY 1107) or capecitabine, 5-FU (fluorouracil).
- •HIV Positive.
- •Ineligible result of HBV, HCV by the investigator.
- •Acute or severe infection.
- •Subjects who take a Sorivudine or brivudine in combination.
- •Subjects who take a combination of tegafur, gimeracil and oteracil potassium or discontinue within 7 days at the screening.
- •Subjects who take a Rifampin and azole class antifungal drugs in combination.
- •Subjects who has labortory findings of inadequate bone marrow, kidney and liver function.
- •Pregnant women, breastfeeding women, or positive findings on the pregnancy test at screening.
- •Subjects with life expectancy of less than 12 weeks by the investigator.
- •Subjects who had been administered other IP within 4 weeks prior to screening.
- •Subjects determined by the investigator to be ineligible for participation in this trial.
研究组 & 干预措施
BEY1107 + Capecitabine
Experimental
Administer BEY1107 in combination with Capecitabine, 3-weeks as 1 cycle.
干预措施: Capecitabine (Combination Product)
BEY1107 + Capecitabine
Experimental
Administer BEY1107 in combination with Capecitabine, 3-weeks as 1 cycle.
干预措施: BEY1107 (Drug)
结局指标
主要结局
Objective Response Rate(ORR)(Phase 2) assessed by investigator following administration of BEY1107 in combination with Capecitabine
时间窗: From baseline up to disease progression, approximately 54 weeks
ORR defined as proportion of subjects with a overall response of CR or PR
Maximum Tolerated Dose(MTD) assessed by investigator following administration of BEY1107 in combination with Capecitabine
时间窗: From baseline up to disease progression, approximately 54 weeks
MTD will be assessed based on adverse events(including DLT assessment), vital signs, 12-lead ECG, laboratory tests, etc.
次要结局
- Pharmacokinetic(PK) of Maximum Serum Concentration (Cmax) of BEY1107 in combination with Capecitabine(From baseline up to 24 hour post-dose)
- Pharmacokinetic of Time to Reach Maximum Serum Concentration (Tmax) of BEY1107 in combination with Capecitabine(From baseline up to 24 hour post-dose)
- Pharmacokinetic of Area Under the Serum Concentration-Time Curve Up to Last Quantifiable Time (AUClast) of BEY1107 in combination with Capecitabine(From baseline up to 24 hour post-dose)
- Progression-free survival(PFS) assessed by investigator following administration of BEY1107 in combination with Capecitabine(From baseline up to disease progression, approximately 24 months)
- Disease control rate(DCR) assessed by investigator following administration of BEY1107 in combination with Capecitabine(From baseline up to approximately 24 months)
研究者
研究点 (1)
Loading locations...
相似试验
招募中
1 期
A Study to Evaluate Safety and Efficacy of BEY1107 in Combination with Temozolomide in Patients with Recurrent or Progressive Glioblastoma Multiforme (GBM)Glioblastoma MultiformeNCT05769660BeyondBio Inc.12
已完成
1 期
A First in Human Study of BAY2701439 to Look at Safety, How the Body Absorbs, Distributes and Excretes the Drug, and How Well the Drug Works in Participants With Advanced Cancer Expressing the HER2 ProteinCancers With HER2 ExpressionNCT04147819Bayer14
已完成
1 期
Dose Escalation Pan-FGFR (Fibroblast Growth Factor Receptor) Inhibitor (Rogaratinib)NeoplasmsNCT01976741Bayer168
终止
1 期
BAY1238097, First in ManNeoplasmsNCT02369029Bayer8
已完成
1 期
Clinical Study to Evaluate Safety and Maximum Tolerated Dose of BAY1000394 Given in a 4 Week on / 2 Week Off Schedule in Subjects With Advanced MalignanciesNeoplasmsNCT01335256Bayer10